Join Growin Stock Community!
Beta
Back to 4116.TW Analysis

Ticker

Value

empty

There is no following symbol in this watchlist.

  • EPS
  • EPS Diluted
  • Revenue
  • Operation Income
  • Net Income
  • Operating Expenses
  • Cash Flow
  • Cash & Debt
  • Current Contract Liabilities
revenue-chart

4116 Revenue

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

明基醫 (4116.TW) 2026Q1 financial report shows revenue of 1.32B TWD, with a YoY growth rate of 7.87%. This figure indicates that 明基醫 (4116.TW)’s operational performance has remained fundamentally stable. The moderate growth rate reflects a relatively steady market environment. Investors are advised to continuously and closely monitor the company’s future quarterly financial performance and key strategic adjustments. For a more comprehensive and objective assessment of 明基醫 (4116.TW)’s future growth potential and investment opportunities, it is recommended to incorporate Growin AI Value Analysis for a thorough and prudent evaluation.